Form 4: Adaptive Bio CEO Sells Shares Under 10b5-1 Plan

Adaptive Biotechnologies CEO and Chairman Chad M. Robins reported the sale of 89,265 shares of common stock over three days in November 2025, pursuant to a Rule 10b5-1 trading plan.

Summary

• Chad M. Robins, CEO and Chairman of Adaptive Biotechnologies Corp (ADPT), reported the sale of 89,265 shares of common stock.
• The sales occurred on November 10, 2025, November 11, 2025, and November 12, 2025.
• On November 10, 2025, 86,161 shares were sold at a weighted average price of $14.73, with prices ranging from $14.37 to $15.05.
• On November 11, 2025, 1,237 shares were sold at a weighted average price of $14.57, with prices ranging from $14.52 to $14.66.
• On November 12, 2025, 1,867 shares were sold at a weighted average price of $15.00, with prices ranging from $15.00 to $15.03.
• These transactions were executed under a Rule 10b5-1 trading plan adopted by Mr. Robins on August 11, 2025.
• Following these transactions, Mr. Robins beneficially owns 2,869,975 shares of common stock directly.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to insider selling, but mitigated by the fact that the sales were pre-planned under a Rule 10b5-1 trading plan, suggesting a structured approach rather than an immediate reaction to company performance.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, which indicates a structured approach to managing personal holdings and reduces concerns about opportunistic insider selling.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by investors as it reduces the insider's direct equity stake in the company.

Risks

• While the sales were pre-planned, a consistent pattern of insider selling by key executives could potentially signal a lack of confidence in the company's future prospects, which could impact investor sentiment.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This insider transaction report reflects a routine disclosure of stock sales by a senior executive. It does not provide specific insights into broader industry trends or competitive landscape, but such sales are common across various industries for personal financial planning.

Corporate Governance

Stakeholder Impact

• Shareholders may interpret the insider selling as a signal, though the pre-planned nature under a 10b5-1 plan typically lessens negative implications compared to unplanned sales.

Key Dates

Recommendation

While insider selling can sometimes be a bearish signal, the transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests personal financial planning rather than a sudden loss of confidence in the company. Without additional financial or operational updates, this Form 4 alone does not provide a strong enough signal for a 'buy' or 'sell' recommendation, thus a 'hold' stance is appropriate.

Keywords

ADPT, Adaptive Biotechnologies, Chad M. Robins, Insider Trading, Form 4, Stock Sale, CEO, Chairman, 10b5-1 Plan, Beneficial Ownership